Step 1 of 2
Bispecific antibody therapy continues to rapidly change the care of patients with R/R multiple myeloma, but these drugs are associated with adverse events that must be managed for patients to remain on therapy long term. In this text module, experts provide learners with illustrated evidence-based information on CRS, ICANS, and infection. Key insights on what symptoms to monitor in patients during step-up dosing and maintenance phases are provided. Details about formulary management, REMS requirements, and standardized protocols used in multidisciplinary patient care are also discussed.